PUBLISHER: IMARC | PRODUCT CODE: 1298765
PUBLISHER: IMARC | PRODUCT CODE: 1298765
Anti-Tuberculosis Therapeutics Market by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2023-2028
The global anti-tuberculosis therapeutics market size reached US$ 1,354.79 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,991.34 Million by 2028, exhibiting a growth rate (CAGR) of 6.70% during 2023-2028. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.
Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.
Anti-Tuberculosis Therapeutics Market Trends:
One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.
Disease Type Insights:
Active TB
Latent TB
Others
The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.
Diagnosis and Treatment Insights:
Diagnosis
Blood Tests
Imaging Tests
Sputum Tests
Others
Treatment
First-Line of Drugs
Isoniazid
Ethambutol
Rifampin
Others
Second-Line of Drugs
Thiacetazone
Paraaminosalicyclic Acid (PAS)
Others
Others
A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicyclic acid (PAS), and others), and others
End User Insights:
Hospitals
Specialty Clinics
Homecare
Others
The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.
Regional Insights:
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market?
- What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market?
- What are the key regional markets?
- Which countries represent the most attractive anti-tuberculosis therapeutics market?
- What is the breakup of the market based on the disease type?
- Which is the most attractive disease type in the anti-tuberculosis therapeutics market?
- What is the breakup of the market based on the diagnosis and treatment?
- Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market?
- What is the breakup of the market based on end user?
- Which is the most attractive end user in the anti-tuberculosis therapeutics market?
- What is the competitive structure of the global anti-tuberculosis therapeutics market?
- Who are the key players/companies in the global anti-tuberculosis therapeutics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Anti-Tuberculosis Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Disease Type
- 6.1 Active TB
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Latent TB
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Diagnosis and Treatment
- 7.1 Diagnosis
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Blood Tests
- 7.1.2.2 Imaging Tests
- 7.1.2.3 Sputum Tests
- 7.1.2.4 Others
- 7.1.3 Market Forecast
- 7.2 Treatment
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 First-Line of Drugs
- 7.2.2.1.1 Major Types
- 7.2.2.1.1.1 Isoniazid
- 7.2.2.1.1.2 Ethambutol
- 7.2.2.1.1.3 Rifampin
- 7.2.2.1.1.4 Others
- 7.2.2.2 Second-Line of Drugs
- 7.2.2.2.1 Major Types
- 7.2.2.2.1.1 Thiacetazone
- 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
- 7.2.2.2.1.3 Others
- 7.2.2.3 Others
- 7.2.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Homecare
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 F. Hoffmann-La Roche Ltd.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 SWOT Analysis
- 14.3.2 Lannett Company Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Lupin Limited
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Macleods Pharmaceuticals Limited
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Otsuka Pharmaceutical Co. Ltd
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.1 F. Hoffmann-La Roche Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
List of Figures
- Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
- Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017-2022
- Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2022
- Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2022
- Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2022
- Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2022
- Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
- Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2022
- Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
- Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
- Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2022 & 2028
- Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
- Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million US$), 2023-2028
- Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
- Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
- Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
- Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players
